A Novel Biomarker for the Acute Kidney Injury in the Cirrhotic Patients

Nae-Yun Heo

doi:10.4166/kjg.2019.74.4.191

Journal List > Korean J Gastroenterol > v.74(4) > 1135710

Go to TopGo to Top Go to BottomGo to Bottom

See the article "".

TOOLS

Heo: A Novel Biomarker for the Acute Kidney Injury in the Cirrhotic Patients

Editorial

The Korean Journal of Gastroenterology 2019; 74(4): 191-192.

Published online: 25 October 2019

DOI: https://doi.org/10.4166/kjg.2019.74.4.191

A Novel Biomarker for the Acute Kidney Injury in the Cirrhotic Patients

Nae-Yun Heo

Division of Gastroenterology, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.

Correspondence to: Nae-Yun Heo, Division of Gastroenterology, Inje University Haeundae Paik Hospital, Inje University College of Medicine, 875 Haeun-daero, Haeundae-gu, Busan 48108, Korea. Tel: +82-51-797-2446, Fax: +82-51-797-1340, nyheo@hanmail.net

Korean Society of Gastroenterology

(open-access):

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Notes

^{Financial support} None.

^{Conflict of interest} None.

References

1. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008; 48:2064–2077.

2. Schrier RW, Shchekochikhin D. Assessment of renal function in heart failure. J Am Coll Cardiol. 2012; 59:1716–1718.

3. Warner NS, Cuthbert JA, Bhore R, Rockey DC. Acute kidney injury and chronic kidney disease in hospitalized patients with cirrhosis. J Investig Med. 2011; 59:1244–1251.

4. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: ascites and related complications. Clin Mol Hepatol. 2018; 24:230–277.

5. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol. 2008; 48 Suppl 1:S93–S103.

6. Alsaad AA, Wadei HM. Fractional excretion of sodium in hepatorenal syndrome: clinical and pathological correlation. World J Hepatol. 2016; 8:1497–1501.

7. Fagundes C, Pépin MN, Guevara M, et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol. 2012; 57:267–273.

8. Schrier RW. Diagnostic value of urinary sodium, chloride, urea, and flow. J Am Soc Nephrol. 2011; 22:1610–1613.

9. Gill N, Nally JV Jr, Fatica RA. Renal failure secondary to acute tubular necrosis: epidemiology, diagnosis, and management. Chest. 2005; 128:2847–2863.

10. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003; 14:2534–2543.

11. Lee JH, Yoon EL, Park SE, et al. Clinical significance of urinary neutrophil gelatinase-associated lipocalin levels in defining the various etiologies of acute kidney injury in liver cirrhosis patients. Korean J Gastroenterol. 2019; 74:212–218.

12. Belcher JM, Sanyal AJ, Peixoto AJ, et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology. 2014; 60:622–632.

13. Francoz C, Nadim MK, Durand F. Kidney biomarkers in cirrhosis. J Hepatol. 2016; 65:809–824.

14. Gungor G, Ataseven H, Demir A, et al. Neutrophil gelatinase-associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: a prospective observational study. Liver Int. 2014; 34:49–57.

TOOLS

ORCID iDs: Nae-Yun Heo
https://orcid.org/0000-0001-6571-8935
Similar articles